On Monday, Shares of SINA Corp (NASDAQ:SINA), added 0.92% and closed at 75.98 in the last trading session. The last trading range of the stock ranges between $74.08 and 76.01. SINA Corporation, through its auxiliaries, operates as an online media company in the Peoples Republic of China. It operates SINA.com, an online brand advertising portal that provides region-focused format and content, counting multimedia news; business news coverage and personal finance columns; sporting events news; automobile-related news; entertainment news and events; technology updates; interactive video products, such as news, sports, entertainment, and education; and education, digital, fashion, eLadies, luxury, health, collectibles, travel, and other interest-based channels. The company also offers SINA mobile, a mobile portal, which provides news information and entertainment content from SINA.com for mobile users in mobile browser and application format. In addition, it operates Weibo.com that offers self-expression products to facilitate users to express themselves on Weibo platform; social products to promote social interaction between users on Weibo platform; discovery products to assist users discover content; notifications, games, VIP membership, and mobile apps; advertising and marketing solutions; and tools and application programming interfaces. Further, the company offers MVAS, which allow users to receive news and information, download ring tones, mobile games and pictures, customize caller ring back tones, and take part in dating and friendship communities. In Addition To, it operates game portal that provides users with downloads and gateway access to online games, information and updates on online and PC games, and value-added application tools. The company also provides eReading, a one-stop shop for book reviews; and free email, VIP mail, and corporate email services for enterprise users, in addition to operates a Website for bloggers to publish and read original writings.
ImmunoCellular Therapeutics Ltd (NYSEMK:IMUC),dropped -5.80% and closed at $0.0844 in the last trading session. The last trading range of the stock ranges between 0.08 and 0.09. The company’s Market capitalization is $11.84 million with the total Outstanding Shares of 137.80 million. ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing other therapeutic DC vaccines, such as ICT-140 for ovarian cancer; and ICT-121 to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer.